LUCD News

Mettler-Toledo (MTD) delivered earnings and revenue surprises of +3.80% and +2.28%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive YearPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid...

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumPR NewswireNEW YORK, Nov. 4, 2026 NEW YORK, Nov. 4, 2026 /PRNewswire...

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard Study Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard StudyPR NewswireNEW YORK, Nov. 3, 2026 Largest peer-reviewed study of nonendoscopic esophageal precancer testing to...

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026PR NewswireNEW YORK, Oct. 30, 2026 Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 30, 2026...

Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026PR NewswireNEW YORK, Oct. 29, 2026 Conference Call and Webcast at 8:30 AM ETNEW...

Confirmation that Medicare is now paying for a cancer-screening test sent its developer sharply higher on Friday. Lucid Diagnostics Inc. (NASDAQ: LUCD), a New York cancer-prevention diagnostics company and subsidiary of medical technology company PAVmed Inc. (NASDAQ: PAVM), said it has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test. The company also closed a $15.0M private placement of Series C convertible preferred stock with existing long-term shareholders on October 21.Recall, Lucid said on September 22 that it would begin submitting Medicare claims for ...

Confirmation that Medicare is now paying for a cancer-screening test sent its developer sharply higher on Friday. Lucid Diagnostics Inc. (NASDAQ: LUCD), a New York cancer-prevention diagnostics company and subsidiary of medical technology company PAVmed Inc. (NASDAQ: PAVM), said it has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test. The company also closed a $15.0M private placement of Series C convertible preferred stock with existing long-term shareholders on October 21.Recall, Lucid said on September 22 that it would begin submitting Medicare claims for ...

With U.S. crude hovering just above $100 a barrel, 247 Market News is watching Kraig Biocraft Laboratories (OTCQB:KBLB), Hyperscale Data (NYSEAMERICAN:GPUS), Lucid Diagnostics (NASDAQ:LUCD), 22nd Century Group (NASDAQ:XXII), and Safe Harbor Financial (NASDAQ:SHFS).